Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. (Q47671221)

4 February 2018

title

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. (English)

1 reference

4 February 2018

0 references

1 reference

Stein EA

1

1 reference

4 February 2018

Davidson MH

2

1 reference

4 February 2018

Dobs AS

3

1 reference

4 February 2018

Schrott H

4

1 reference

4 February 2018

Dujovne CA

5

1 reference

4 February 2018

Bays H

6

1 reference

4 February 2018

Weiss SR

7

1 reference

4 February 2018

Melino MR

8

1 reference

4 February 2018

Stepanavage ME

9

1 reference

4 February 2018

Mitchel YB

10

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 August 1998

1 reference

4 February 2018

American Journal of Cardiology

published in

1 reference

4 February 2018

volume

82

1 reference

4 February 2018

page(s)

311-316

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900421-4

10.1016/S0002-9149(98)00421-4

7 January 2021

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

9708659

1 reference

4 February 2018